GlassScriptPhysician profile
Bernard Kadosh
NPI 1861836645
$5,288.98
in general payments reported to CMS, 2019-2025
26 companies · $902 in 2025
The $902 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,729 · 2020: $44.81 · 2021: $363 · 2022: $682 · 2023: $1,031 · 2024: $537 · 2025: $902.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,327 · Travel and Lodging: $143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,326.76 |
| Travel and Lodging | $143.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $1,049.98 | 2019 | |
| Abbott Laboratories | $958.98 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Novartis Pharmaceuticals Corporation | $549.79 | 2019-2025 | |
| Endotronix, INC. | $416.81 | 2021-2025 | Cordella Pulomonary Artery Pressure Sensor |
| Merck Sharp & Dohme LLC | $302.05 | 2023-2025 | Verquvo, Capvaxive, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $285.38 | 2021-2023 | Jardiance |
| Pfizer INC. | $260.80 | 2022-2025 | |
| Daiichi Sankyo INC. | $203.83 | 2022-2023 | Injectafer |
| Irhythm Technologies, INC. | $195.30 | 2019-2023 | Zio Xt Patch |
| Astrazeneca Pharmaceuticals LP | $165.94 | 2021-2025 | Farxiga, Wainua |
| Janssen Pharmaceuticals, INC | $137.06 | 2019-2023 | Xarelto |
| Abiomed | $128.09 | 2024-2025 | Impella |
| Scpharmaceuticals INC. | $106.66 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $82.69 | 2019-2021 | |
| Amgen INC. | $75.47 | 2019-2024 | Repatha |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ancora Heart, INC. | $74.04 | 2024-2025 | Accucinch |
| Kestra Medical Technology Services, INC. | $53.91 | 2025 | Assure Wcd |
| Boston Scientific Corporation | $44.43 | 2019 | |
| Cvrx, INC. | $35.57 | 2025 | Barostim Neo System |
| Alnylam Pharmaceuticals INC. | $35.50 | 2025 | Amvuttra |
| One Lambda, INC. | $33.64 | 2024 | |
| Heartflow, INC. | $25.71 | 2019 | |
| Vifor Pharma, INC. | $19.34 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.64 | 2023 | |
| Sensible Medical Innovations INC | $15.73 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.64 | 2025 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernard Kadosh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.